Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Neurology

The Biology of Neurogenic AMC and the Diagnostic Journey

At a Glance

Neurogenic AMC occurs when nerve cells fail to send proper movement signals, causing a lack of fetal movement that leads to joint contractures. Modern diagnosis relies on comprehensive genetic testing rather than invasive biopsies, making it critical to quickly identify specific gene variants and rule out treatable conditions like Spinal Muscular Atrophy (SMA).

Understanding the biology behind Neurogenic Arthrogryposis Multiplex Congenita (AMC) is a key step in moving from the shock of diagnosis to an empowered plan for care. In this form of AMC, the joints and muscles are often healthy at the start of development, but they become “stuck” because of a breakdown in communication from the nervous system [1][2].

The Biological “Bad Actor”: The Nervous System

The root cause of Neurogenic AMC lies in the motor neurons—the specialized cells in the spinal cord (specifically the anterior horn cells) and brainstem that tell muscles to move [3][4].

  • The Chain Reaction: When these nerve cells fail to send signals correctly, the limbs cannot move effectively in the womb [3][5].
  • Fetal Akinesia: This lack of movement, called fetal akinesia, is the primary driver of joint contractures [5][2]. Just as a hinge can rust if never used, a developing joint that does not move will fix in place, leading to the stiffness seen at birth [5].
  • Secondary Effects: Because the muscles aren’t being “exercised” by nerve signals, they may become thin or weak (atrophy), which further stabilizes the joint in a fixed position [6][3].

Distinguishing the Types of AMC

It is helpful to understand how Neurogenic AMC differs from other forms:

  • Myogenic (Muscle-Based) AMC: Here, the problem is within the muscle itself, while the nerves are functioning normally [7][6].
  • Amyoplasia: This is a “sporadic” (non-genetic) form of AMC often caused by blood flow issues in the womb. It usually involves severe muscle loss but typically does not affect the brain or spine [8][9].
  • Neurogenic AMC: This is specifically a “wiring” issue where the nervous system is the source of the reduced movement [3][1].

The Modern Diagnostic Journey

In the past, doctors relied on invasive muscle biopsies (removing a piece of muscle tissue) or EMG/NCS (using needles to test nerve electricity) to find answers. Today, the “first-tier” tool has changed [10][11].

Why Genetic Testing First?

Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) are now the preferred starting points [10][12]. These tests analyze DNA to find the exact genetic “typo” causing the condition. This approach is:

  • Less Invasive: It usually requires only a simple blood draw or cheek swab [13].
  • More Precise: It can identify specific genes, providing a much clearer picture of what to expect than a biopsy could [14][15].
  • Cost-Effective: By skipping a long “diagnostic odyssey” of multiple smaller tests, it often leads to an answer faster [10][16].

The “Critical Rule-Out”: Spinal Muscular Atrophy (SMA)

One of the most important reasons for rapid genetic testing is to rule out Spinal Muscular Atrophy (SMA) [17][18]. SMA is a neurogenic condition that can present exactly like other forms of AMC at birth.

Ruling out SMA is critical because early intervention with disease-modifying therapies can be life-changing for many SMA variants [19][20]. However, it is important to know that SMA Type 0 (prenatal onset) involves severe, irreversible prenatal damage and carries a very poor prognosis [17]. Rapid testing is crucial to identify the type and explore any viable interventions.

Your “Completeness Checklist”

To ensure a thorough evaluation, your medical team should ideally complete the following:

  1. Genetic Sequencing (WES/WGS): To find the underlying genetic cause [21].
  2. SMA Testing (SMN1/SMN2): To rule out this specific condition [19].
  3. MRI of Brain and Spine: To look for physical signs of nerve or brain development issues [22][23].
  4. Swallow Study: Neurogenic issues can affect the muscles used for swallowing, leading to “silent” choking (aspiration) [24][25].
  5. Multi-specialty Review: Ensuring a neurologist, geneticist, and orthopedic surgeon are all coordinating the diagnostic data [26][27].

Common questions in this guide

What causes Neurogenic AMC?
Neurogenic AMC is caused by a communication breakdown in the nervous system. Motor neurons in the spinal cord and brainstem fail to send correct movement signals to the muscles, leading to a lack of movement in the womb that causes joints to become stiff and fixed in place.
Why is genetic testing recommended for an AMC diagnosis?
Genetic testing, such as Whole Exome Sequencing, can pinpoint the exact genetic cause of the condition without the need for invasive muscle biopsies. This approach is faster, less painful, and provides precise answers to guide your child's care plan.
Why is it so important to test for Spinal Muscular Atrophy (SMA)?
SMA is a specific neurogenic condition that can present exactly like other forms of AMC at birth. It is critical to rule it out quickly because early intervention with disease-modifying therapies can be life-changing for many types of SMA.
Is a swallowing study necessary for a child with Neurogenic AMC?
Yes, because the nervous system issues that cause AMC can also affect the muscles used for swallowing. A formal swallowing study helps identify 'silent' choking or aspiration, ensuring that feeding is safe.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has Spinal Muscular Atrophy (SMA) been definitively ruled out using an SMN1/SMN2 genetic test?
  2. 2.What specific gene variant was identified in the genetic testing, and what does this mean for the long-term outlook?
  3. 3.Is a formal swallowing study (VFSS) necessary to ensure safe feeding without silent aspiration?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Fetal Akinesia/Hypokinesia and Arthrogryposis of Neuromuscular Origin: Etiologic Groups, Genetics, and Phenotypic Spectrum.

    Pérez-Vidarte F, Estévez-Arias B, Matalonga L, et al.

    Annals of clinical and translational neurology 2025; (12(8)):1528-1547 doi:10.1002/acn3.70088.

    PMID: 40443119
  2. 2

    Arthrogryposis multiplex congenita-an update.

    Møller-Madsen B

    Journal of children's orthopaedics 2015; (9(6)):425-6 doi:10.1007/s11832-015-0688-2.

    PMID: 26482521
  3. 3

    Congenital Zika syndrome with arthrogryposis: retrospective case series study.

    van der Linden V, Filho EL, Lins OG, et al.

    BMJ (Clinical research ed.) 2016; (354()):i3899 doi:10.1136/bmj.i3899.

    PMID: 27509902
  4. 4

    De novo variant in KIF26B is associated with pontocerebellar hypoplasia with infantile spinal muscular atrophy.

    Wojcik MH, Okada K, Prabhu SP, et al.

    American journal of medical genetics. Part A 2018; (176(12)):2623-2629 doi:10.1002/ajmg.a.40493.

    PMID: 30151950
  5. 5

    Intra-familial variability associated with recessive RYR1 mutation diagnosed prenatally by exome sequencing.

    Casey J, Flood K, Ennis S, et al.

    Prenatal diagnosis 2016; (36(11)):1020-1026 doi:10.1002/pd.4925.

    PMID: 27616680
  6. 6

    Case Report: Prenatal Diagnosis of Nemaline Myopathy.

    Liu D, Yu J, Wang X, et al.

    Frontiers in pediatrics 2022; (10()):937668 doi:10.3389/fped.2022.937668.

    PMID: 35928692
  7. 7

    Mutations in the NEB gene cause fetal akinesia/arthrogryposis multiplex congenita.

    Feingold-Zadok M, Chitayat D, Chong K, et al.

    Prenatal diagnosis 2017; (37(2)):144-150 doi:10.1002/pd.4977.

    PMID: 27933661
  8. 8

    Using the Term Amyoplasia Loosely Can Lead to Confusion.

    Hall JG

    American journal of human genetics 2020; (107(6)):1186-1187 doi:10.1016/j.ajhg.2020.10.014.

    PMID: 33275911
  9. 9

    Fetuses and infants with Amyoplasia congenita in congenital Zika syndrome: The evidence of a viral cause. A narrative review of 144 cases.

    Hageman G, Nihom J

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2023; (42()):1-14 doi:10.1016/j.ejpn.2022.11.002.

    PMID: 36442412
  10. 10

    [Exome diagnostics in neurology].

    Zech M, Wagner M, Schormair B, et al.

    Der Nervenarzt 2019; (90(2)):131-137 doi:10.1007/s00115-018-0667-1.

    PMID: 30645660
  11. 11

    Genetic testing for diagnosing neurodevelopmental disorders and epilepsy: a systematic review and meta-analysis.

    Chang YM, Huang YT, Lai PC

    Systematic reviews 2025; (14(1)):155 doi:10.1186/s13643-025-02896-y.

    PMID: 40722196
  12. 12

    Current scenario of the genetic testing for rare neurological disorders exploiting next generation sequencing.

    Di Resta C, Pipitone GB, Carrera P, Ferrari M

    Neural regeneration research 2021; (16(3)):475-481 doi:10.4103/1673-5374.293135.

    PMID: 32985468
  13. 13

    Comparison of first-tier whole-exome sequencing with a multi-step traditional approach for diagnosing paediatric outpatients: An Italian prospective study.

    Rosina E, Pezzani L, Apuril E, et al.

    Molecular genetics & genomic medicine 2024; (12(1)):e2316 doi:10.1002/mgg3.2316.

    PMID: 38041506
  14. 14

    Collaborating to advance interdisciplinary care for individuals with arthrogryposis.

    Dahan-Oliel N, Hall JG

    American journal of medical genetics. Part C, Seminars in medical genetics 2019; (181(3)):273-276 doi:10.1002/ajmg.c.31741.

    PMID: 31471949
  15. 15

    De novo mutations of SCN1A are responsible for arthrogryposis broadening the SCN1A-related phenotypes.

    Jaber D, Gitiaux C, Blesson S, et al.

    Journal of medical genetics 2021; (58(11)):737-742 doi:10.1136/jmedgenet-2020-107166.

    PMID: 32928894
  16. 16

    Genetics of mitochondrial diseases: Identifying mutations to help diagnosis.

    Stenton SL, Prokisch H

    EBioMedicine 2020; (56()):102784 doi:10.1016/j.ebiom.2020.102784.

    PMID: 32454403
  17. 17

    Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.

    Matesanz SE, Curry C, Gross B, et al.

    Journal of child neurology 2020; (35(11)):717-723 doi:10.1177/0883073820928784.

    PMID: 32515646
  18. 18

    Skin necrosis in spinal muscular atrophy: Case report and review of the literature.

    Weissman AS, Kennedy KR, Powell MR, Davis LS

    Pediatric dermatology 2021; (38(3)):632-636 doi:10.1111/pde.14538.

    PMID: 33619801
  19. 19

    Diagnostic Testing for Patients with Spinal Muscular Atrophy.

    Brandsema JF, Gross BN, Matesanz SE

    Clinics in laboratory medicine 2020; (40(3)):357-367 doi:10.1016/j.cll.2020.05.005.

    PMID: 32718505
  20. 20

    The need for evidence-based treatment decisions in spinal muscular atrophy type 0.

    Erbas Y, Gusset N

    Annals of clinical and translational neurology 2021; (8(10)):2094-2095 doi:10.1002/acn3.51459.

    PMID: 34546649
  21. 21

    A review of the orthopedic interventions and functional outcomes among a cohort of 114 children with arthrogryposis multiplex congenita.

    Hansen-Jaumard D, Elfassy C, Montpetit K, et al.

    Journal of pediatric rehabilitation medicine 2020; (13(3)):263-271 doi:10.3233/PRM-190657.

    PMID: 33104047
  22. 22

    Severe brain involvement in 5q spinal muscular atrophy type 0.

    Mendonça RH, Rocha AJ, Lozano-Arango A, et al.

    Annals of neurology 2019; (86(3)):458-462 doi:10.1002/ana.25549.

    PMID: 31301241
  23. 23

    Absence of Axoglial Paranodal Junctions in a Child With CNTNAP1 Mutations, Hypomyelination, and Arthrogryposis.

    Conant A, Curiel J, Pizzino A, et al.

    Journal of child neurology 2018; (33(10)):642-650 doi:10.1177/0883073818776157.

    PMID: 29882456
  24. 24

    Disability in adults with arthrogryposis is severe, partly invisible, and varies by genotype.

    Dai S, Dieterich K, Jaeger M, et al.

    Neurology 2018; (90(18)):e1596-e1604 doi:10.1212/WNL.0000000000005418.

    PMID: 29626181
  25. 25

    Pena-Shokeir syndrome: current management strategies and palliative care.

    Adam S, Coetzee M, Honey EM

    The application of clinical genetics 2018; (11()):111-120 doi:10.2147/TACG.S154643.

    PMID: 30498368
  26. 26

    Characterization of a group unrelated patients with arthrogryposis multiplex congenita.

    Valdés-Flores M, Casas-Avila L, Hernández-Zamora E, et al.

    Jornal de pediatria 2016; (92(1)):58-64.

    PMID: 26453511
  27. 27

    Rehabilitation in Patients Diagnosed with Arthrogryposis Multiplex Congenita: A Systematic Review.

    García Aguilar CE, García-Muñoz C, Carmona-Barrientos I, et al.

    Children (Basel, Switzerland) 2023; (10(5)) doi:10.3390/children10050768.

    PMID: 37238316

This page explains the biology and diagnostic process of Neurogenic AMC for educational purposes. Always consult a pediatric neurologist or medical geneticist for specific diagnostic testing and medical advice for your child.

Get notified when new evidence is published on Neurogenic arthrogryposis multiplex congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.